Jared Gollob
Vermögen: 8 Mio $ am 30.06.2026
Vermögen: 8 Mio $ am 30.06.2026
Jared Gollob worked at Duke University from 2002 to 2007 as Director of the Biologic Therapy Program.
From 2007 to 2018, worked at Alnylam Pharmaceuticals, Inc., serving as Global VP of Medical Affairs and Clinical Development from 2012 to 2018.
From 2018 to 2026, worked at Kymera Therapeutics, Inc. as Chief Medical Officer.
Former jobs include Director-Biologic Therapy Program at Duke University and Global VP-Medical Affairs & Clinical Development at Alnylam Pharmaceuticals, Inc.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 31.03.2026 | 71.359 ( 0,09 % ) | 8 Mio $ | 30.06.2026 |
| Unternehmen | Position | Ende |
|---|---|---|
| KYMERA THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 27.07.2026 |
| ALNYLAM PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.08.2018 |
Duke University
Duke University Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01.09.2007 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 4 |
|---|---|
The Trustees of Columbia University in The City of New York
The Trustees of Columbia University in The City of New York Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Duke University
Duke University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics based on RNA interference | Health Technology |
Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops immunology medicines for health problems | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen